The effects of inhalation and percutaneous exposure to disodium- hexachloroplatinate (16923583) (HCP) on dermal and bronchial hypersensitivity were studied in monkeys. Biweekly for 12 weeks, monkeys were exposed to nose only inhalation of 0.2 or 2.0 milligrams per cubic meter (mg/m3) HCP aerosol for 4 hours, were exposed percutaneously to 1 milliliter (ml) of 20mg/ml HCP, or were untreated. Before and after the exposure regimens, cutaneous reactions were assessed after intradermal injections of HCP at 0.2 to 1000 micrograms/ml. Two weeks after final exposure, bronchial provocation challenges were performed for 1 minute each with saline and five HCP solutions from 0.1 to 62.5mg/ml, and pulmonary function parameters were assessed. Preexposure and postexposure dermal sensitivities did not differ for any animal. There were no significant differences in pulmonary function among groups after saline bronchial provocation. After challenge with 62.5mg/ml HCP, control values were decreased 10 to 47 percent from post saline control values for forced vital capacity (FVC), peak expiratory flow rate, forced expiratory volume (FEV) in 0.5 second to FVC ratio, and forced expiratory flows at 50, 25, and 10 percent of VC to FVC ratios; average pulmonary flow resistance (PFR) was increased 347 percent. Treated group values generally did not differ from control values, except for a 957 percent increase in PFR and a 31 percent decrease in FEV/FVC in the 0.2mg/m3 inhalation group. The authors conclude that intradermal sensitivity to HCP is not related to previous exposure. Bronchial sensitivity may also be seen in previously unexposed test animals, probably due to a pharmacologic or irritant mediated bronchoconstriction mechanism.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.